Efficacy and Safety of Tocilizumab Biosimilars Compared to Reference Tocilizumab in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

INTRODUCTION

Tocilizumab biosimilars offer an innovative therapeutic option for pa-tients with rheumatoid arthritis (RA); however, their safety and efficacy compared with the refer-ence product remain undefined. This systematic review and meta-analysis aim to synthesize data from all randomized clinical trials (RCTs) comparing the efficacy and safety of tocilizumab bio-similars with reference tocilizumab for RA treatment.

METHODS

Following PRISMA guidelines, we searched PubMed, the Cochrane Library, and Web of Science up to March 2026. We included RCTs comparing biosimilars of tocilizumab to refer-ence tocilizumab in adult RA patients. Primary efficacy outcomes included ACR20 response and DAS28-ESR; secondary outcomes were ACR50/70, DAS28-CRP, and safety outcomes.

RESULTS

Four Phase 3 double-blind RCTs enrolling 2160 patients were included in the analysis. No statistically significant differences were found between biosimilars and reference tocilizumab for ACR20, ACR50, or ACR70 DAS28-CRP responses at 12, 24 weeks, and approximately 1 year. Similarly, no difference was observed in DAS28-ESR change from baseline at 12 (MD, -0.07; P = 0.26) or 24 weeks (MD, -0.04; P = 0.60). However, at approximately 1 year (48-52 weeks), biosimilars showed a statistically significantly greater reduction in DAS28-ESR (MD -0.24, 95% CI: -0.44 to -0.05; P = 0.01) but did not reach the minimal clinically important differ-ence (MCID). Safety profiles were comparable, with no significant differences in safety out-comes.

DISCUSSION: Our results indicate that tocilizumab biosimilars are therapeutically equivalent to the reference product in terms of clinical response and safety. However, a primary limitation of this meta-analysis is the small number of included RCTs. Future research should prioritize long-term surveillance and cost-effectiveness analysis in diverse settings to facilitate widespread clinical adoption and ensure sustained patient safety.

CONCLUSION

Our meta-analysis shows that tocilizumab biosimilars have efficacy and safety pro-files equivalent to those of reference tocilizumab for the treatment of RA. These findings support the use of biosimilars as an effective therapeutic alternative.